MANAGEMENT TEAM OF LIPUM
Dr Einar Pontén, CEO
Dr Pontén received his PhD in analytical chemistry at Umeå University, but started 1984 as pharmaceutical analytical chemist at Astra Draco AB i Lund, Sweden. He co-founded and managed the pioneering chromatography company SeQuant AB, that eventually was acquired by Merck KGaA (Darmstadt) in year 2008. Einar was then CEO of Merck SeQuant AB until he returned to business development of academic start-ups in 2012. Einar is also chairman of the board of directors in Biotech i Kungsbacka AB.
Dr Susanne Lindquist, CSO
Dr Lindquist received her PhD in microbiology and she has 15 years of research on the bile salt-stimulated lipase (BSSL) enzyme and more than 20 original scientific paper in peer reviewed journals. Susanne has expertise in animal models of arthritis and other inflammatory diseases. She also holds a position as Senior research engineer at Department of Clinical Sciences at Umeå University.
Dr Pernilla Abrahamsson, COO
Dr Abrahamsson received her PhD in Anesthesiology and Intensive Care at Umeå University 2010. During her PhD she invented an advanced medical device (OnZurf Probe) for sampling in connection to postoperative monitoring. She started MD Biomedical AB that was acquired by Senzime AB in year 2015. Pernillas has then worked with product development, marketing and sales at Senzime. Pernilla has more than 20 years experience of medical science and 10 years of MedTech and entrepreneurship.
Dr Mats Reslow, CMC Project manager
Mats Reslow is a research and development professional with more than 25 years of experience in biopharmaceuticals and drug delivery. He has a proven record of developing projects from early research through clinical development and regulatory submission. He worked as Head of Research in Bioglan Therapeutics AB and SkyePharma. Between 2004 and 2016, he was a Principal Scientist at NovoNordisk A/S, coordinating the processing related to drug delivery and life cycle management of proteins, antibodies/fragment and protein conjugates within growth disorders, diabetes, haemophilia and inflammation. Since 2016, he has been an independent consultant advising on drug development, formulation, CMC, IPR, and intelligence.